DG DISPATCH - ISH: Droloxifene Lowers Blood Pressure In Healthy Postmenopausal Women
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - ISH: Droloxifene Lowers Blood Pressure In Healthy Postmenopausal Women

By Lara Pullen
Special to DG News

CHICAGO, IL -- August 23, 2000 -- Droloxifene is the first selective estrogen receptor modulator (SERM) shown to lower blood pressure in healthy postmenopausal women.

At the 18th Scientific Meeting of the International Society of Hypertension (ISH), Dr. K. Bridget Brosnihan of the Wake Forest University School of Medicine, Winston-Salem, NC, presented the results of a study which compared the effects on blood pressure of conjugated equine estrogen and the tamoxifen analogue, droloxifene.

The study included 24 healthy postmenopausal women between the ages of 50 and 65 years. The women had fasting low-density lipopolysaccharide levels of less than 200 mg/dL and triglyceride levels of less than 400 mg/dL.

The women had an average systolic blood pressure (SBP) of 133 and an average diastolic blood pressure (DBP) of 72.

While conjugated equine estrogen had no effect on blood pressure levels, droloxifene significantly reduced blood pressure levels (5 percent decrease for SBP and 8 percent decrease for DBP).

Both estrogen and droloxifene increased the levels of plasma angiotensin II, although neither had a significant effect on angiotensin I.

Dr. Brosnihan noted that these results were seen in healthy women with no cardiovascular risk and the research needs to be expanded to include a larger group of women with varying degrees of cardiovascular risk.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities